Hormonal
Bariatric surgery, particularly Roux-en-Y gastric bypass (RYGB), significantly improves psoriasis symptoms and quality of life, with effects potentially linked to increased GLP-1 levels post-surgery.
If you have severe obesity and psoriasis, and lifestyle changes plus medications haven't worked, bariatric surgery (especially gastric bypass) can be a powerful option. It not only helps with weight but can significantly improve your psoriasis symptoms, likely by boosting your body's natural GLP-1 levels. This is a major step, so it's reserved for those with higher BMI or uncontrolled comorbidities.
This type of intervention appears to have a beneficial effect on patients with psoriasis. This effect is clearer following gastric bypass surgery than vertical gastrectomy. One possible explanation for this is that GLP-1 levels increase beyond physiological levels after bypass surgery.
Why this rating
Based on observational studies and prospective cohorts, not large-scale RCTs.
Source
Management of Obesity in Psoriasis Consultations
Joana Nicolau et al. · Dermatology and Therapy · 2026
DOI 10.1007/s13555-026-01664-7
More from this paper
- GLP-1 receptor agonists (liraglutide 3 mg, semaglutide 2.4 mg) and tirzepatide are effective first-line pharmacological treatments for obesity in psoriasis patients, providing significant weight loss and independent improvements in psoriasis severity (PASI scores) through anti-inflammatory mechanisms.Good
- Lifestyle interventions, specifically the Mediterranean diet and moderate-to-vigorous exercise, improve psoriasis symptoms and quality of life, independent of weight loss.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →